Endocrine Abstracts

Introduction: Giant prolactinomas are rare tumours, they represent range from 0.5 to 4.0% of all pituitary tumours. We are presenting a patient with giant prolactinoma without visual field defects and any obvious clinical symptoms related to hyperprolactinemia and probably associated with alopecia universalis.Case: 32 years old man has visited outpatient department of our hospital, complaining of severe headache for the last three years. He underwent bra...

Introduction: Pituitary adenomas are benign intracranial tumors. However, some of them are resistant to multiple medical treatments and are clinically considered to be aggressive.Case report: Twenty years old male patient presented with symptomatic hyperglycemia and general weakness. With suspected diagnosis of type 1 diabetes patient was hospitalized in Kauno Klinikos, Endocrinology Department. In further clinical observation acromegalic appearance noti...

Introduction: GH producing pituitary adenomas are associated with infertility. Hereby the first case in Lithuania, when acromegaly patient got pregnant and delivered is reported.Case presentation: 33-year-old woman visited endocrinologist complaining of secondary amenorrhoea. Due to elevated prolactin – 3016 mU/l (NR<418), bromcriptine treatment was started. The patient discontinued treatment after three months because of restoration of regular ...

Adult patients with acromegaly after pituitary adenomas usually have emotional problems, impaired quality of life. Objective was to detect possible differences of emotional state between patients with acromegaly after pituitary adenomas and healthy age- and sex-matched controls and to outline possible gender-specific differences.Patients and methods: 12 males (age 49.6±10.2 years) and 29 females (age 51.5±9.5 years) with acromegaly after pituit...

Introduction: Stereotactic radiotherapy and more relevant pharmacotherapy are widely used for PA’s treatment; however transsphenoidal surgery remains gold standard. Postoperative complications and endocrinological outcomes vary widely and are related with surgeon experience and tumor characteristics.The aim of this study: To determine relationship between pituitary adenoma size and transsphenoidal pituitary adenoma surgery outcomes.<p class="abs...

Introduction: ACTH producing macroadenoma and pituitary apoplexy are rare in Cushing’s disease. Somatostatin receptor agonist Pasireotide is indicated for the treatment of patients with Cushing’s disease for whom surgery is not an option or has failed. We present a case of pituitary apoplexy in patient with recurrence of Cushing’s disease treated with Pasireotide.Case: 38 years old female presented with quick weight gain, weakness, irregul...

Inconsistences in hirsutism evaluation using The Modified Ferriman-Gallwey scale (mFG) between different evaluators and need for hirsutism diagnostics standardization has been reported in numerous publications.The aim of the study was to determine the differences in the evaluation of female hirsutism between researchers.Results: The study included healthy 20–34 year old (mean age 25.2 years, 95% CI 23.8–26.5) women with r...

Introduction: The number of studies on the incidence and outcomes of surgical treatment for pituitary adenomas is still limited, despite that pituitary tumours are one of the most frequent intracranial tumours.The aim of this study: To evaluate clinical features of transsphenoidaly operated pituitary adenomas (PA) and perioperative results of the treatment.Materials and methods: This is a retrospective single institution study of 4...

Spontaneous remission of Cushing disease might be a phase of cyclic disease, but could also be explained by an ACTH-microadenoma infarction or hemorrhage. True remission must be differentiated from cyclic Cushing’s disease with prolonged follow up. 63-years-old female patient was referred to endocrinologist’s and presented with uncontrolled hypertension, type 2 diabetes, central obesity, hirsutism, swelling of the face and legs and a ’buffalo hump’. After a...

BackgroundPatients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA®) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been first-line medical treatment for patients with acromegaly for decades. OOC are newly approved in the US for patients previously controlled on iSRL...